Studies oncologie
Snel naar
- Studies fase 1 / basket oncologie
- Studies borstkanker
- Studies gynaecologische oncologie
- Studies digestieve oncologie
- Studies neuro-endocriene tumoren (NET)
- Studies hoofd- en halsoncologie
- Studies musculoskeletale oncologie (tumoren van de weke delen)
- Studies hersenkanker
- Studies urologische oncologie
- Studies dermatologische oncologie (huidtumoren)
- Studies thoraxoncologie
- Studies pijncentrum
University Clinical Research Center Antwerp (UNICCRA)
De research unit is een onderdeel van de oncologische afdeling binnen het UZA. Het doel van de research unit is nieuwe, betere en steeds meer doeltreffendere behandelingen vinden om kankerpatiënten te behandelen. Klinische studies zijn hiervoor de beste methode. Tijdens deze klinische studies kunnen onze onderzoekers bepalen welke behandelingen veiliger, effectiever en beter zijn dan huidige behandelingen. De research unit bestaat uit artsen, studie coördinatoren, logistieke medewerkers, studie verpleegkundigen, pathologen en administratieve medewerkers.
Hoe kan ik de research unit bereiken?
Heb je vragen over de studies binnen de research unit? Neem gerust contact met ons op via 03 821 55 80, 03 821 53 07 of via research [dot] oncologie [at] uza [dot] be.
Studies fase 1/basket oncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
MCLA-145-CL01: A Phase 1, Open-label, Dose-escalation study of MCLA-145 in participants with advanced or metastatic malignancies |
|
<=4L |
|
Slots | |
MATTERS: A mono-centric, first in-human (FIH), safety and preliminary efficacy study of (neo)adjuvant, model-based, whole-body hyperthermia (WBHT) treatment in advanced solid cancer patients or stage IV (TxNxM1) metastatic pancreatic adenocarcinoma patients |
Solid - stage IV | All |
|
Open | NCT04467593 |
EZH-1201: A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects with Moderate and Severe Hepatic Impairment with Advanced Malignancies. |
All tumortypes with:
|
Prior SOC |
|
Slots |
NCT04241835 |
TRIDENT-1: A Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements |
|
|
|
Open | |
TAPISTRY/BO41932: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study |
|
|
|
Open | |
MCLA-129: Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors |
|
|
|
Slots | |
GO42144: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation |
KRAS G12C mutated
|
Prior SOC or intolerance |
|
Slots | |
BT5528-100: A Phase I/II study of BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
|
|
|
Slots | |
AMG 20190135: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation |
|
|
|
Slots | NCT04185883 |
CL1-95012-001: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors |
Solid tumors |
|
|
Slots | NCT05159388 |
20210023 (AMG193): AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP) |
Selected tumor types with lost MTAP expression (central testing)
|
|
|
Slots | NCT03564340 |
20210104 (AMG 552): A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) |
|
|
|
Slots | NCT05325866 |
WP43295: A phase 1a/b open-label study to evaluate safety, pharmacokinetics, and preliminary clinical activity of RO7276389 alone and in combination with cobimetinib in participants with BRAF-V600 mutation-positive advanced solid tumor or BRAF-V600 mutation-positive melanoma with central nervous system metastases |
|
Prior SOC |
|
Slots | ISRCTN13713551 |
61186372GIC2002 (ORIGAMI-1): A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer |
CRC with KRAS/NRAS/BRAF/EGFR/HER2 wild type
|
|
|
Slots | NCT05379595 |
20200469: A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer |
|
1L |
|
Slots | NCT05361395 |
MK6482-016: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors |
|
|
|
Slots | NCT04976634 |
KBA1412-101: A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumors |
|
|
|
Slots | NCT05501821 |
DAY101-102: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations |
All solid tumors with:
|
Prior SOC or intolerant |
|
Slots | NCT04985604 |
DO2.22.01: A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours |
All solid tumors with:
|
|
|
Slots | |
1403-0011 (Brightline-2): A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours |
MDM2 amplified, TP53 wild-type solid tumours:
|
|
|
Open | NCT05512377 |
INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies |
Part 2: dose expansion
|
<= 2L |
|
Slots | NCT05577182 |
1456-0001: Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors |
All solid tumors with accessible tumor lesions
|
Prior SOC or ineligible |
|
Slots | NCT05155332 |
GO43860: A Phase IA/IB, open label, multicenter, dose-escalation study to evaluate the safety, pharmacokinetics, and activity of RO7502175 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors |
Selected solid tumors with PD-L1 >=1% (>=10% for esophageal) Phase 1A: monotherapy
Phase 1B: combination therapy
|
Prior SOC |
|
Slots | NCT05581004 |
PYX-201-101: A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors |
|
Prior SOC |
|
Slots | NCT05720117 |
IMC-F106C-101: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers |
HLA-A*02:01-positive and PRAME-positive solid tumors
Currently enrolling:
Pre-screening only allowed for:
Will be eligible with new amendment:
|
Prior SOC or intolerant/ineligible |
|
Open | NCT04262466 |
XB002-101 (JEWEL101): A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors |
All cohorts temporarily on hold
|
|
|
On hold | NCT04925284 |
JK08.1.01: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients with Unresectable Locally Advanced or Metastatic Cancer |
Dose escalation (currently open):
|
Prior SOC or intolerant/ineligible
|
|
Slots | NCT05620134 |
GCT1047-01: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors |
|
|
|
Open | NCT05180474 |
Bayer 21820: First-in-human dose-escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of the anti-CCR8 antibody BAY 3375968 as monotherapy and in combination with pembrolizumab in participants with selected advanced solid tumors |
Dose escalation (currently open):
|
Prior SOC |
|
Slots | NCT05537740 |
OPTIMIZE-1: An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma |
Pancreatic ductal adenocarcinoma (PDAC)
|
1L |
|
Slots | NCT04888312 |
Studies borstkanker
Title | Tumortype | Line of therapy | Study information | Status | Register |
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence | HER2- / HR+ | Adjuvant |
|
Open | NCT05774951 |
TROPION-Breast03: Randomized, Open-label Phase 3 study of Datopotamab Deruxtecan with or without Durvalumab vs Investigator's Choice therapy in patients with stage I-III TNBC | TNBC (no BRCA1 or BRCA2 mutation) | Adjuvant |
|
Open | NCT05629585 |
TACTIVE-U/C4891024: An interventional safety and efficacy Phase 1b/2, open-label umbrella study to investigate tolerability, PK, and antitumor activity of ARV-471 (PF-07850327), an oral Proteolysis Targeting Chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer. |
HER2-/ER+ | 1-3L |
|
Open | NCT05548127 |
ELECTRA/ELA-0121: An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from ER Positive, HER-2 Negative Breast Cancer |
HER2-/ER+ | 2-3L |
|
Open | NCT05386108 |
C4891001 / Veritac-2: A Phase 3, Randomized, Open-Label, Multicenter Trial Of Arv-471 (Pf-07850327) Vs Fulvestrant In Participants With Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment For Advanced Disease.
|
HER2-/ER+ | 2-3L |
|
Open | NCT05654623 |
VIKTORIA-1/CELC-G-301: A Phase 3, Open-Label, Randomized, Three-Arm Study of Gedatolisib Plus Palbociclib plus Fulvestrant and Gedatolisib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Patients Previously Treated with a CDK4/6 Inhibitor |
HER2-/ER+ | 2-3L |
|
Open | NCT05501886 |
INAVO121/WO43919: a Phase III, multicenter, randomized, open-label, global study designed to compare the efficacy and safety of inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with HR +/HER2 - , PIK3CA-mutated LA/mBC, who progressed during or after CDK4/6i-plus endocrine therapy. |
HER2-/HR+ | 2-3L |
|
Open | NCT05646862 |
AIPAC-003: A randomized, double-blind, placebo-controlled Phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization |
TNBC and HER2-/HR+ | 1L chemo |
|
Open | NCT05747794 |
Studies gynaecologische oncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
R4018-ONC-1721: Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer |
Ovarian carcinoma of epithelial origin |
|
|
Slots | NCT03564340 |
MK4830-002: Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer |
Ovarian: stage III or IV HGSOC
|
|
|
Open | NCT05446870 |
(IN)CIP-S25470: Cancer in Pregnancy |
Cancer during pregnancy
and in first 5 years after delivery
|
|
|
Open | NCT00330447 |
GE-CIP-S62388: Genomic and Epigenomic Alterations After Cancer Treatment in Pregnancy |
Cancer during pregnancy (any type and stage)
|
|
|
Open | NCT04125446 |
Studies digestieve oncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Intermediate-risk, Stage II-III Rectal Cancer REGINA |
Rectal cancer | Neo-adjuvant |
|
On hold | |
Phase 3 study of perioperative Dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer. 219606 / AZUR-2 |
colon cancer | Neo-adj/adj |
|
Expected | |
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma GO44479 - IMCODE003 |
resectable PDAC | Neo-adj/adj |
|
Expected | |
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer AT148006 ASPEN-06 |
Advanced gastric or gastroesophageal junction | 2L-3L |
|
Closed | |
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression AMGEN 20210096 FORTITUDE-101 |
Advanced gastric or gastroesophageal junction | 1L |
|
Open | |
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen DS8201-A-U306 DESTINY-gastric-04 |
Advanced gastric or gastroesophageal junction | 2L |
|
Open | |
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation MRTX849 KRYSTAL-10 |
Advanced colorectal cancer | 2L |
|
Closed | |
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer AMGEN 20210098 - FORTITUDE-102 |
Unresectable (locally advanced or metastatic) gastric of GEJ adenocarcinoma | 1st line |
|
Open | |
FOLICOLOR Trial: Following therapy response through Liquid Biopsy in metastatic colorectal cancer patients |
(unresectable) Metastatic colorectal Cancer | 1L (2-3L if recurrence) |
|
Open | NCT04735900 |
NALPAC: A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + Naliri and 5-FU + Nalirinox for metastatic pandreatic ductal adenocarcinoma |
Metastatic PDAC | 2L |
|
Open | NCT05472259 |
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined with Chemotherapy, in Patients with advanced cancers. ACTUATE 1801 |
Metastatic PDAC | 1L |
|
Closed | NCT03678883 |
COLIPAN: Collection of Liquid Biopsies in Pancancer patients |
Colon adenoCa, Rectum adenoCa, Pancreas adenoCa, Hepatocellulair Ca, slokdarm plaveiselcel | 1L |
|
Open | |
A Randomised, double–blind, placebo-controlled Trial of Aspirin to prevent Recurrence
ASPIRIN |
Colon Cancer | Adjuvant |
|
Closed for randomization | NCT03464305 |
Open-label, phase 2 trial of Botensilimab as monotherapy and in combination with Balstilimab or investigator’s choice SOC (regorafenib or trifluridine and tipiracil) for refractory metatstatic colorectal cancer.
PROTOCOL C-800-25 Agenus |
Metastatic Colorectal Cancer | >2L |
Exclusion:
|
Hold | NCT05608044 |
A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or mCRC RGX 202-002 |
Advanced or metastatic colorectal cancer | 2L |
|
Open | NCT05983367 |
Personalized multimodal treatment for resectable esophageal cancer by detecting minimal residual disease using circulating tumor DNA: a multicentric prospective study |
New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC) |
Group 1: Patients undertaking primary resection (surgery or endoscopic) with no neoadjuvant chemotherapy or chemoradiation. Group 2: Patients receiving neoadjuvant chemoradiotherapy, followed by resection and observation (no adjuvant immunotherapy). A subgroup of patients will undertake adjuvant immunotherapy and will constitute Group Group 3: Patients undertaking neoadjuvant chemoradiotherapy, resection and adjuvant immunotherapy. |
|
Open | NCT05704530 |
SARTOX |
Gastro-Intestinal Tumour |
Not applicable |
|
Open | |
STEREOPAC |
Pancreatic Adenocarcinoma (Borderline resectable) |
Not applicable |
|
Open | NCT05083247 |
A study of Tucatinib + Trastuzimab + mFOLFOX6 versus standard of care treatment in 1ste line HER2+ mCRC.
SGNTUC-029 / MOUNTAINEER-03 |
mCRC |
1st line |
|
Open | NCT05253651 |
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic HCC. IMbrave152 / CO44668 |
Advanced or metastatic HCC |
1L |
|
Open | NCT05904886 |
Phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety Rego-Pembro versus TACE or TARE for the first-line treatment of HCC TRIO 041 / REPLACE studie |
HCC |
1ste line |
|
Expected | |
A study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients COPERNIC
|
Advanced colorectal cancer |
>= 3L |
|
Open | |
A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma BALLAD
|
Stage I – III small bowel adenocarcinoma |
1L |
|
Open |
|
Efficacy and safety of SCRT versus TNT in older patients with locally advanced rectal cancer SHAPERS |
Rectal Cancer |
1L |
|
Open | |
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer AZUR-2
|
Untreated T4N0M0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
1L |
OR
|
Open | |
WT IL15 DC vaccination Trial: First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients |
Solid tumors - pancreas preferred |
>= 2L; PD on last therapy not needed |
|
With waiting list |
Studies neuro-endocriene tumoren (NET)
Title | Tumor Type | Line of therapy | Study information | Status | Register |
A Trial to Assess Efficacy and Safety of Octreotide (CAM2029) Subcutaneous Depot in Patients With GEP-NET HS-19-657 SORENTO |
GEP-NET |
2L |
|
Closed
|
NCT05050942 |
Liquid-NET 2.0: A prospective, multicentric, proof-of-concept study to evaluate the value of circulating tumour DNA in follow-up of patients with an advanced gastroenteropancreatic or lung neuroendocrine tumour under everolimus ± somatostatin analogues | Metastasized neuroendocrine tumor of gastrointestinal, pancreatic or lung origin | >=2L |
|
Open |
|
Quali-NET: Patient-reported outcomes in neuroendocrine neoplasms: a prospective quality of life and quality of care study within NETwerk | All neuroendocrine neoplasms | All |
|
Open | NCT05268783 |
Collect-NET 2.0 by BE-FORCE: Collection of liquid biopsy samples of patients with neuroendocrine neoplasms | All neuroendocrine neoplasms | All |
|
Open | NA |
DNET registry: a Belgian prospective, national, web-based registry of digestive neuroendocrine tumors | All gastrointestinal neuroendocrine neoplasmsNENs | All |
|
Open | NA |
SAUNA trial: Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients | GEP NET | 2L |
|
Open | NCT05701241 |
Studies hoofd- en halsoncologie
Title | Tumortype | Line of therapy | Study information | Status | Register |
JZJB/LIBRETTO-531: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer |
Thyroid |
1L |
|
On hold | NCT04211337 |
ELEVATE: A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma |
SCCHN:
|
1L |
|
On hold | NCT04854499 |
COLIPAN: collection of Liquid Biopsies in Pancancer patients |
H&N plaveiselcelCa |
1L |
|
Open | |
MS202359_002 XRay Vision: A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy |
Resected LA SCCHN, high risk, cisplatin-ineligible participants |
1L |
|
Open | NCT05386550 |
Hyperlynx: A Single Arm, Open label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy |
Patients with unresected LA SCCHN (stage III, IVA or IVB) |
1L |
|
Open | NCT06056310 |
Studies musculoskeletale oncologie (tumoren van de weke delen)
Title | Tumor Type | Line of therapy | Study information | Status | Register |
Studies hersenkanker
Title | Tumor Type | Line of therapy | Study information | Status | Register |
ADDIT-GLIO: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma | Glioblastoma | Adjuvant |
|
Open | NCT02649582 |
Studies urologische oncologie
Title | Tumor Type | Line of therapy | Study information | Status | Register |
PEACE III: A Randomized phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. | Prostate cancer | >= 1L |
|
open | NCT02194842 |
KEYNOTE-676: A Phase 3, Randomized, Comparator-controlled Clinical Trials to study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction. | Non-muscle invasive bladder carcinoma | Persistent or recurrent following BCG induction |
|
Open | NCT03711032 |
COLIPAN: collection of Liquid Biopsies in Pancancer patients | Prostaat adenoCa | 1L |
|
Open |
Studies dermatologische oncologie (huidtumoren)
Title | Tumor Type | Line of therapy | Study information | Status | Register |
IFX-1-P2.8: Open label, multicenter Phase II study of the C5a-antibody IFX-1 alone or IFX-1 + pembrolizumab in patients with PD-1- or PD-L1-resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) | Cutaneous squamous cell carcinoma |
|
|
Closed | NCT04812535 |
Thoraxoncologie
De dienst thoraxoncologie is een onderdeel van het MOCA (Multidisciplinair Oncologisch Centrum Antwerpen) binnen het UZA. We behandelen patiënten met longkanker, longvlieskanker en thymustumoren. Naast standaard behandelingen bieden we ook behandelingen in studieverband aan. Het gaat hier om fase II en III klinische studies. Het doel van een klinische studie is om te onderzoeken of een nieuwe behandeling veiliger, effectiever en beter is dan huidige behandeling. Voor fase I klinische studies verwijzen we u naar de research unit.
Hoe kan ik de dienst thoraxoncologie bereiken?
Heb je vragen over de studies binnen de dienst thoraxoncologie? Neem gerust contact met ons op via 03 821 56 81 of via research [dot] oncologie [at] uza [dot] be.
Studies thoraxoncologie
Title | Tumor Type | Line of therapy | Study information | Status | Register |
DOLBY-LC01: Clinical verification study of epigenetic biomarker panels for the diagnosis of lung cancer (stage IV) |
NSCLC stage IV and healty subjects |
prior to 1L
|
|
On Hold | |
PACIFIC-8: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab in Participants with Locally Advanced (Stage III), Unresectable NSCLC Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy |
NSCLC stage III |
1L maintenance
|
|
Open | NCT05211895 |
JZJX: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) |
NSCLC stage IB-IIIA, RET fusion |
1L
|
|
Open | NCT04819100 |
KRYSTAL-7: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced NSCLC with KRAS G12C Mutation |
NSCLC stage IIIB-IV, KRAS G12C |
1L
|
|
On hold | NCT04613596 |
PACIFIC-4: Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation |
NSCLC stage I-II, EGFRm |
1L
|
|
Open | NCT03833154 |
HiPeRMESO |
Malignant Pleural Mesothelioma |
1L, after induction chemotherapy and surgery
|
|
Open | |
PRIMALung: PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients |
SCLC limited - extensive stage |
after 1L
|
|
Open | NCT04790253 |
COLIPAN: collection of liquid biopsies in pancancer patients |
NSCLC adenoCa, NSCLC plaveiselcelCa |
1L
|
|
Open | |
LUNG Platform: A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, PD-L1-Selected NSCLC |
NSCLC stage III-IV, PD-L1 high |
1L
|
Open cohorts:
|
Open | NCT05565378 |
LAGOON: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed SCLC Patients |
SCLC limited - extensive stage |
2L
|
|
Open | NCT05153239 |
SAFFRON: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Vs Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic NSCLC Who Have Progressed on Treatment With Osimertinib |
NSCLC stage III-IV, EGFRm |
2-3L
|
|
Open | NCT05261399 |
LONG 20-06: development of a blood test for prediction of response and toxicity to immunotherapy in lung cancer |
NSCLC |
1L
|
|
Open | / |
TeliMET NSCLC-01: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous NSCLC |
NSCLC stage III-IV |
>1L
|
|
Open | NCT04928846 |
DDRiver NSCLC 322: An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous NSCLC that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies |
NSCLC stage III-IV |
>1L
|
|
On hold | NCT05882734 |
Be6A LUNG-01: A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated NSCLC |
NSCLC stage IIIb-IV |
>1L
|
|
Open | NCT06012435 |
Pijncentrum
Heb je vragen over de studies van het pijncentrum? Neem gerust contact met ons op via +32 3 436 81 65 (Eva Wauters) of via studies [dot] pijncentrum [at] uza [dot] be.
Studies pijncentrum
Title | Tumor Type | Line of therapy | Study information | Status | Register |
ATX01-22-01-CIPN: A multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15% w/w) in comparison to placebo, in cancer survivor adult patients with chemotherapy-induced peripheral neuropathy (CIPN) |
Adult cancer survivor patients with CIPN / polyneuropathy (hands and/or feet) (treated by taxanes or platins or any other neurotoxic chemotherapy) | Patients who stopped their chemotherapy treatment for >= 24 weeks at the time of screening visit |
|
Open |